
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics Inc is positioned for a positive financial outlook due to its innovative gene therapy platform TRACER, which has the potential to yield durable efficacy with a single administration and addresses significant unmet needs in neurological diseases. The company retains co-commercialization options for its key programs, which enhances its long-term revenue potential and could provide critical clinical validation of its technology in human trials. Moreover, the successful advancement of its robust pipeline, alongside an extended cash runway into mid-2027, allows Voyager to focus on developing compelling treatments, potentially creating substantial value for shareholders.
Bears say
Voyager Therapeutics exhibits a negative financial outlook primarily due to its inability to generate sales revenue, coupled with a reported net loss of ($1.13) per share, indicating significant financial challenges that may hinder future profitability. The company's reliance on the success of its gene therapy programs, particularly VY7523 and VY9323, carries substantial risks as they face competition from more advanced tau antibody programs and could fail to demonstrate the necessary efficacy in clinical trials. Additionally, potential delays or unfavorable regulatory decisions further compound the risks, as any setbacks in progress or approval could adversely impact revenue projections and overall valuation estimates.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares